Boehringer seeks FDA nod for Pradaxa antidote idarucizumab
This article was originally published in Scrip
Executive Summary
In submitting a biologics license application (BLA) for idarucizumab to the FDA, Boehringer Ingelheim is seeking to be the first company with a anticoagulant reversal agent on the US market.